Marksans Pharma Limited (MARKSANS) Q2 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Cofacto Research Published October 30, 2026 5 min read

Marksans Pharma, a Mumbai-headquartered formulations maker with a 26 billion unit annual capacity across the US, UK and India, reports its Q2 FY 2026-2027 numbers after a record Q1 that delivered 25.3% EBITDA margin and Rs. 1,058 Cr of cash. The print will hinge on how far gross margin normalises from Q1's 59.1% toward the guided 55-56% as low-cost inventory depletes, and on the first consolidated quarter of the newly acquired ABCnow (Germany).

Quick Details

Results date	November 04, 2026
Quarter	Q2 FY 2026-2027
Previous quarter revenue	Rs. 840.8 Cr (+35.6% YoY)
Previous quarter PAT	Rs. 159.4 Cr (+173.9% YoY)
Previous quarter EBITDA margin	25.3%
Net debt (latest quarter)	Net cash of Rs. 1,031 Cr
Market cap	Rs. 13,886.88 Cr
CMP	Rs. 306.2

Marksans Pharma Limited Q2 Results Date and Time

The Board of Directors will meet on Wednesday, November 4, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The trading window for Designated Persons is closed from October 1, 2026 until 48 hours after the results (up to November 6, 2026).

The Q2 FY27 earnings call is scheduled for Thursday, November 5, 2026, at 4:00 PM IST, organized by Systematix Institutional Equities, to discuss the unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Speakers are Mark Saldanha (Founder, Chairman & MD) and Jitendra Sharma (CFO).

Key Things To Watch

Performance vs guidance tracking: Key management targets to interrogate on the call, latest first:

FY27 revenue growth of 15-20% and EBITDA margin of 20-21% — held despite Q1FY27 printing 35.6% YoY growth and a 25.3% margin; watch whether a second strong quarter prompts a revision
Gross margin guided to stabilise around 55-56% in FY27 — watch the QoQ glide from Q1FY27's 59.1% and the net effect of the give-back against the +781 bps operating-leverage gain
Employee benefit expenses to streamline to 13-13.5% of revenue by Q2 FY27 — directly testable in this quarter's numbers
QliniQ revenue of Rs. 150-175 Cr for FY27 (Rs. 44 Cr in Q1) and Europe including QliniQ of approximately Rs. 180 Cr — probe the quarterly phasing; Germany 'meaningful revenue' promised by early Q3 FY27

ABCnow consolidation and M&A pipeline

ABCnow GmbH (Germany) consolidates from Q2 FY27 — ask for its first-quarter revenue contribution and integration/start-up costs
Further European acquisitions guided for FY27, with active due diligence on one target and another under evaluation, funded from cash of Rs. 1,058 Cr — a balance-sheet drawdown or new borrowing would flag a deal in progress

Raw material inflation and US order book conversion

Whether the 20-30% petroleum-related ingredient inflation starts biting as pre-built inventory (which covered Q1 'to a great extent') depletes, and whether hoped-for price correction materialises
US order book of $220 Mn+ with a 5-6 month award-to-commercialisation lag and P&L visibility promised from Q1/Q2 FY27; ~50 US launches planned for FY27 against the $300 Mn order-book target by FY28
US trade policy: management is monitoring the 200% duty mention but generics were clarified as exempt from the Section 232 tariffs, with India among jurisdictions eligible for zero-tariff treatment on qualifying specialty drugs

Frequently Asked Questions

Why did Marksans Pharma not raise its FY27 guidance after a record Q1?

Management held the FY27 guidance of 15-20% revenue growth and 20-21% EBITDA margin despite Q1FY27's 35.6% YoY revenue growth and 25.3% EBITDA margin. Mark Saldanha said, 'No, I think we'll stick with that plan because of the volatility that you see, the geopolitical scenarios that you see prevailing.'

Is Marksans Pharma on track for its Rs. 4,000 Cr revenue target?

Management reaffirmed on the Q4FY26 and Q1FY27 calls that the Rs. 4,000 Cr revenue target is for FY28, saying 'INR4,000 crores within the next 2 years is very much on the plate right now.' On the earlier Q3FY26 call the same target had been framed as 'FY28 or FY29.'

Can Marksans Pharma hold 20-21% EBITDA margins despite raw material inflation?

Asked whether FY27 EBITDA margins would stay at 20-21% despite raw material price inflation, management responded, 'No, I think it will be the same.' The company has simultaneously guided gross margin to stabilise around 55-56% from Q1FY27's 59.1% as favourable inventory depletes.

What drove Marksans Pharma's record Q1 FY27 results?

Q1FY27 revenue rose 35.6% YoY to Rs. 840.8 Cr, with UK & Europe contributing Rs. 152 Cr of the Rs. 221 Cr YoY increase (including Rs. 44 Cr from the newly consolidated QliniQ), and EBITDA margin expanded 919 bps YoY to 25.3% on gross margin improvement and operating leverage. PAT rose 173.9% YoY to Rs. 159.4 Cr, helped by a lower effective tax rate of 22.8%.

How does Marksans Pharma plan to use its cash reserves?

Cash crossed Rs. 1,000 Cr for the first time at Rs. 1,058 Cr in Q1FY27, which management says provides flexibility for organic growth and 'calibrated inorganic opportunities', with M&A activity guided for FY27 and active due diligence on one European target. An analyst has also flagged that the cash largely earns 4-5% post-tax in FDs and current accounts against an operating ROC of 20%.